US Stock Futures Gain Ahead Of Macy's Earnings - Anheuser-Busch InBev (NYSE:BUD)

Pre-open movers

US stock futures traded higher in early pre-market trade.

Macy's, Inc. M

is estimated to report its quarterly earnings at $0.54 per share on revenue of $6.09 billion. Futures for the Dow Jones Industrial Average jumped 50 points to 17,766.0, while the Standard & Poor's 500 index futures rose 6 points to 2,084.00. Futures for the Nasdaq 100 index surged 12.50 points to 4,655.50.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index rising 0.77 percent, STOXX Europe 600 Index jumping 0.71 percent and German DAX 30 index gaining 1.04 percent. French CAC 40 Index surged 0.68 percent and London's FTSE 100 Index rose 0.44 percent. In Asian markets, Japan's Nikkei Stock jumped 0.10 percent, Hong Kong's Hang Seng Index fell 0.22 percent, China's Shanghai Composite Index gained 0.27 percent.

Broker Recommendation

Analysts at Bernstein downgraded

SanDisk CorporationSNDK

from Outperform to Market Perform. SanDisk shares fell 1.57 percent to close at $75.70 on Tuesday.

Breaking news

Molson Coors Brewing Company TAP today announced that it has entered into a definitive agreement with Anheuser Busch Inbev SA (ADR) BUD to purchase SABMiller plc's (ADR) SBMRY 58% stake in MillerCoors, the joint venture formed in the United States by SABMiller and Molson Coors in 2008. To read the full news, click here.
Premier Inc PINC priced an underwritten public offering on Tuesday, of 4,033,198 shares of Class A common stock at $34.50 per share on behalf of certain selling member-owner stockholders who elected to participate in the offering, as contemplated by a registration rights agreement executed in connection with Premier's initial public offering. To read the full news, click here.
Five Prime Therapeutics Inc FPRX announced that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvement Acts of 1976 (HSR Act) in connection with the exclusive worldwide license and collaboration agreement with Bristol-Myers Squibb (BMS) for the development and commercialization of Five Prime's colony stimulating factor 1 receptor (CSF1R) antibody program, including FPA008. To read the full news, click here.
Sanofi SA (ADR) SNY and Regeneron Pharmaceuticals Inc REGN today announced a new post-hoc analysis of six Phase 3 clinical trials showing that approximately three quarters (74 percent) of patients reached their pre-specified LDL cholesterol targets within 8 weeks of adding Praluent® (alirocumab) Injection 75 mg to their standard-of-care, which included statins. To read the full news, click here.

Market News and Data brought to you by Benzinga APIs